with clinical data. Br-J Caoncer (in press) Taghian A. Ramsay J. Allanunis-Turner J, Budach W, Gioioso D. Pardo F, Okunieff P, Bleehen N. Urtasun R and Suit H (1993) Reply to the letter from B Stausb0olGr0n et al Sir,
The above letter reports the predominant growth of fibroblasts rather than tumour cells in soft agar cultures of cervix carcinomas. It then suggests that results generated by my co-workers and I (West et al, 1997) show that 'it may be likely that' fibroblast radiosensitivity predicts clinical outcome after radiotherapy in cervix cancer (Stausb0l-Gr0n et al, 1998) . There are four reasons why I believe they cannot translate their experience to our results. First, there is the issue of antibody cross-specificity. This problem is most clearly demonstrated from a study on human lung tumours cultured in soft agar (Lawton et al, 1995) . In the worst case, three of four colonies examined showed positive staining with cytokeratin markers and eight of eight colonies showed positive staining with a fibroblast marker (5B5). That is, for the same tumour, 75% of the colonies grown were tumour marker positive and 100% were fibroblast marker positive. The 5B5 monoclonal antibody stains prolyl 4-hydroxylase, which is involved in collagen synthesis and has been reported to be specific for fibroblasts (Esterre et al, 1992) . However, both human endothelial (Schwachula et al. 1994 ) and macrophage (Labat et al, 1991) cells have been shown to express 5B5. Although, to my knowledge, it has not been studied in tumours, it is possible that some will express 5B5. The cervix tumour work of Stausb0l-Gr0n and co-workers (1998) used the anti-vimentin monoclonal antibody 3B4 as a marker for fibroblast cells. Unfortunately, vimentin expression is not fibroblast specific. Vimentin expression in tumour cells may be a feature of dedifferentiation, and it has been reported for a variety of tumour types: breast tumours (Gould et al, 1990) , sarcomas (Gerharz et al, 1990) , carcinomas of the vulva (Weikel et al, 1996) , lung carcinomas (Blobel et al, 1984) and endometrial carcinomas (Mobus et al, 1993) . In addition, in a series of four cervix carcinoma lines, two squamous cell carcinomas were shown to be positive for vimentin expression (Kelland et al, 1987) . To complicate the situation further, tumours can not only express vimentin but they can also lose keratin expression during cell division (Lane et al, 1982) and culture (Mackay et al, 1990) . In support of this, rapidly proliferating tumours have been shown to have a lower proportion of cytokeratin-positive tumour cells (Wingren et al, 1995) .
In our own work, we have looked at low-molecular-weight cytokeratin expression in some cervix tumours (Davidson et al, 1992) . Nine tumours were examined using CAM5.2 (recognizing cytokeratins 8, 18 and 19) and CKI (recognizing cytokeratins 6 and 18) antibodies, and positive staining of colonies was seen. Although the majority was positive using both stains, two tumours were CAM5.2 positive and CK1 negative, showing the importance of using multiple cytokeratin markers.
Secondly, there is a difference in the method used by the Aarhus and Manchester groups. In culturing human tumours, we use an enzyme cocktail followed by a half-hour disaggregation in trypsin (omitted by the Aarhus group), which is used at a fivefold higher concentration than used for the routine subculture of monolayer cells. Trypsin is known to be toxic to fibroblasts and must be used at a low concentration for a short period of time. Indeed, selective trypsinization is used in establishing epithelial cultures to prevent overgrowth by fibroblasts (e.g. Schumann et al, 1988) . In addition, we have quantified the cell types present in cell suspensions prepared using enzymes from cervix tumours (Davidson et al, 1992) . The predominant cell type present is tumour (mean 45%) followed by granulocyte (mean 24%), lymphocyte (mean 16%) and macrophage (mean 15%). Fibroblast-like cells are seen rarely. Time after treatment (months) Figure 1 The relationship between colony-forming efficiency (CFE) and outcome in 128 cervix carcinomas treated with radiotherapy. Patients were stratified according to the median value of CFE (0.06%), which was obtained before treatment using a soft agar clonogenic assay. The lower arm represents patients with tumour CFE greater than the median. Follow-up times ranged from 2 to 5 years with a median of 47 months. The P-values are the results of univariate log-rank analyses Thirdly, there is circumstantial evidence from our data that supports the fact that predominantly tumour colonies grow in agar. The ability of tumours to grow in agar is measured as colonyforming efficiency (CFE) which is considered to reflect tumour stem cell content. Despite the errors involved in measuring CFE (Davidson et al, 1990) , it is a significant prognostic factor for local control after radiotherapy (Figure 1 ). There is no reason why fibroblast CFE would predict local recurrence or reflect tumour stem cell content.
Finally, measurements of fibroblast SF, commonly range from 0.15 to 0.40 (Dahlberg et al, 1993; Burnet et al, 1994) . This contrasts with the higher range of values reported for 'fibroblasts' from cervix tumours (range 0.28-1.00), which is more compatible with the range expected for tumour cells
As described above, we believe that the evidence strongly supports the proposition that we are growing predominantly tumour and not fibroblast colonies. However, the suggestion has been made by Stausb0l-Gr0n and co-workers (1998) that we are probably measuring fibroblast radiosensitivity, which is then an independent prognostic factor for the response of cervix tumours to radiotherapy. There are two analyses that may help clarify this issue. One would be to examine fibroblast radiosensitivity in relation to treatment outcome in the Aarhus series of breast cancer patients (Johansen et al, 1996) . The other would be the Aarhus correlations of fibroblast/tumour radiosensitivity with clinical outcome, which, if they are accurately identifying fibroblast colony contamination with their selective assessment method, should improve the value of SF2 measurements of primary tumour biopsies in cancer of the cervix. Letters to the Editor 553
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Bcl2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance Sir,
We were interested to read the recent article by Pepper et al (Br J Cancer 76: 935-938, 1997) . This paper discussed flow cytometric quantitation of apoptosis as a measure of responsiveness to chemotherapy in B-cell chronic lymphocytic leukaemia (B-CLL), with particular reference to Bcl-2/Bax protein ratios. Our group, using the same antibodies, is pursuing very similar research in superficial bladder cancer. We have compared percentages of positively staining Bcl-2 and Bax tumour cells before and after in vitro exposure to mitomycin C in bladder tumours. We have obtained results (unpublished) which would further support the theory that Bax dysregulation plays an important role in chemoresistant tumours (Boersma et al, 1997; Chresta et al, 1996) . As the next stage to our own experiments, we would be very keen to investigate co-expression of Bcl-2 and Bax in the bladder tumour cells using flow cytometry. Co-expression would indicate the extent of heterodimerization of Bcl-2 with Bax that is likely to affect the inhibition of apoptosis after chemotherapy (Yang et al, 1995) . We were therefore very interested to read the authors' description of a triple-colour flow cytometry methodology in B-CLL cells. They described how they sequentially incubated the cells with anti-CD19 Cy5 PEconjugated antibody, Bcl-2 FITC and Bax followed by PElabelled secondary antibody. Unfortunately, the authors did not report their findings on the co-expression of Bcl-2 and Bax in the B-CLL cells.
Secondly, the paper did not report the Bcl-2 and Bax protein levels in their clinically untreated patient samples after in vitro exposure to chlorambucil. Considering our own findings, which showed a correlation between apoptotic index > 10% and increased Bax protein, these data would have been very relevant.
Thirdly, we were confused by the fact that the authors confirmed that the Annexin V-positive Iymphocytes cells were apoptotic by morphological assessment. Annexin V binds to cells in the early stages of apoptosis, are not all likely to exhibit the classical features of apoptosis (Martin et al, 1995) . It would be interesting to know what criteria the authors used to confirm that the Annexin V-positive lymphocytes were or were not in early apoptosis.
In summary, the authors designed an important study, but unfortunately they did not exploit or report all of their data. The quantification of Bcl-2 and Bax proteins was achieved by triple-colour analysis as described in our paper, and the co-expression of Bcl-2 and Bax was measured in these experiments. However, our data relate to protein expression in the total gated B-lymphocyte population of cells rather than to individual cell analysis; all gated cells expressed both Bcl-2 and Bax proteins. The index we used to describe this co-expression was a ratio of the two proteins (Bcl-2/Bax) as there is evidence that the ratio of death promoters to death inhibitors within the cell may determine susceptibility to death signals (Korsmeyer et al, 1993; Thomas et al, 1996; Pepper et al, 1996) . These ratios were calculated as
